No Data
No Data
Express News | CytoMed Therapeutics Shares Are Trading Higher After the Company Announced That Its Subsidiary, IPSC Depository, Acquired the License and Certain Assets of Cellsafe International for Approximately $490,000 to Be Funded From Internal Cash Resources
Express News | Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources
Express News | Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
CytoMed Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/11/2024 150.04% Benchmark $5 → $5 Reiterates Speculative Buy → Speculative Buy 12/04/2023 150.04% Bench
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
CytoMed Therapeutics Announces Upcoming AGM
No Data